FDA grants orphan drug designation to Reolysin

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Orphan Drug Designation to Reolysin, developed by Oncolytics Biotech Inc., for the treatment of ovarian cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login